Inventor · disambiguated record
Sunil Chada
Also filed as: CHADA SUNIL · CHADA SUNIL D
12 granted patents·26 pending applications·303 citations·filing 1994–2022
92Inventor score
Top patents by PatentIndex Score
38 records- 0193US6333195B1Crossless retroviral vectorsCHIRON CORP·Filed 2000·Granted Dec 25, 2001·41 cites·44 claims
- 0287US9402919B2Vectors conditionally expressing proteinROETH JEREMIAH F·Filed 2012·Granted Aug 2, 2016·28 cites·28 claims
- 0386US5693522AAnti-cancer immunotherapeuticsVIAGENE INC·Filed 1995·Granted Dec 2, 1997·70 cites·20 claims
- 0485US6013517ACrossless retroviral vectorsCHIRON CORP·Filed 1997·Granted Jan 11, 2000·61 cites·38 claims
- 0579US8668905B2P53 vaccines for the treatment of cancersANTONIA SCOTT·Filed 2006·Granted Mar 11, 2014·3 cites·35 claims
- 0678US5736388ABacteriophage-mediated gene transfer systems capable of transfecting eukaryotic cellsFiled 1994·Granted Apr 7, 1998·53 cites·4 claims
- 0777US10584351B2Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereofINTREXON CORP·Filed 2017·Granted Mar 10, 2020·2 cites·30 claims
- 0872US5856185AMethod for making reflection defective retroviral vectors for infecting human cellsCHIRON CORP·Filed 1995·Granted Jan 5, 1999·32 cites·18 claims
- 0965US8034790B2Use of MDA-7 to inhibit pathogenic infectious organismsIntrogen Therapeutics·Filed 2004·Granted Oct 11, 2011·2 cites·32 claims
- 1064US2020239906A1Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereofINTREXON CORP·Filed 2020·Application pending·0 cites
- 1163US7423015B1Antihelminthic drugs as a treatment for hyperproliferative diseasesUNIV TEXAS·Filed 2002·Granted Sep 9, 2008·2 cites·57 claims
- 1260US2015044240A1P53 vaccines for the treatment of cancersUNIV SOUTH FLORIDA·Filed 2014·Application pending·0 cites
- 1359US12454561B2Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancerMULTIVIR INC·Filed 2019·Granted Oct 28, 2025·0 cites·23 claims
- 1457US2006063697A1Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responsesGABRILOVICH DMITRY·Filed 2005·Application pending·0 cites
- 1557US2005171045A1Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responsesVANDERBILT UNIVERSITY AND INTR·Filed 2004·Application pending·0 cites
- 1654US2007231304A1Prognostic factors for anti-hyperproliferative disease gene therapyINTROGEN THERAPEUTICS INC·Filed 2007·Application pending·0 cites
- 1753US2018344876A1Vectors Conditionally Expressing ProteinINTREXON CORP·Filed 2018·Application pending·0 cites
- 1852US2024307470A1Armed seneca valley virus oncolytic therapy compositions and methods thereofSENECA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1951US2024100107A1Seneca valley virus combination therapy to treat a cancer refractory to a checkpoint inhibitorSENECA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2051US2003045499A1Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responsesVANDERBILT UNIVERSITY AND INTR·Filed 2002·Application pending·0 cites
- 2151US2006052322A1Combination treatment of cancer with elicitor of gene product expression and gene-product targeting agentINTROGEN THERAPEUTICS INC·Filed 2005·Application pending·0 cites
- 2250US2016208285A1Vectors Conditionally Expressing Therapeutic Proteins, Host Cells Comprising the Vectors, and Uses ThereofINTREXON CORP·Filed 2015·Application pending·0 cites
- 2349US2007281041A1Compositions and Methods Involving MDA-7 for the Treatment of CancerINTROGEN THERAPEUTICS INC·Filed 2007·Application pending·0 cites
- 2449US2024042061A1Methods and compositions comprising tumor suppressor gene therapy for the inhibition of pathogensMULTIVIR INC·Filed 2021·Application pending·0 cites
- 2548US6410326B1Method for inhibiting human tumor cellsCHIRON CORP·Filed 1995·Granted Jun 25, 2002·9 cites·10 claims
- 2648US2013195800A1Vectors Conditionally Expressing Therapeutic Proteins, Host Cells Comprising the Vectors, and Uses ThereofROETH JEREMIAH F·Filed 2011·Application pending·0 cites
- 2746US2002123479A1Immunostimulation mediated by gene-modified dendritic cellsFiled 2001·Application pending·0 cites
- 2846US2016317678A1Vectors Conditionally Expressing ProteinINTREXON CORP·Filed 2016·Application pending·0 cites
- 2945US2003223967A1Adenoviral p53 gene transfer in the prevention and treatment of injury-induced vascular smooth muscle cell proliferationZUMSTEIN LOUIS·Filed 2003·Application pending·0 cites
- 3044US2022226402A1Methods and compositions comprising enhanced targeted immune gene therapy for the treatment of cancerNORTHSHORE UNIV HEALTH SYSTEM·Filed 2020·Application pending·0 cites
- 3142US2007066552A1Topical administration permitting prolonged exposure of target cells to therapeutic and prophylactic nucleic acidsINTROGEN THERAPEUTICS INC·Filed 2006·Application pending·0 cites
- 3241US2008292592A1Oncolytic Adenovirus Armed with Therapeutic GenesCHADA SUNIL·Filed 2005·Application pending·0 cites
- 3341US2006134801A1Methods and compositions involving MDA-7INTROGEN THERAPEUTICS INC·Filed 2004·Application pending·0 cites
- 3438US2020009203A1Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseasesMULTIVIR INC·Filed 2017·Application pending·0 cites
- 3537US2004009939A1Methods of enhancing immune induction involving MDA-7REGENT THE UNIVERSITY OF TEXAS·Filed 2003·Application pending·0 cites
- 3636US2019038713A1Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancerMULTIVIR INC·Filed 2016·Application pending·0 cites
- 3732US2002183271A1Methods of treatment involving human MDA-7Filed 2001·Application pending·0 cites
- 3829US2002082224A1Non-immunogenic prodrugs and selectable markers for use in gene therapyFiled 1998·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Sunil Chada files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →